These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 25363619)

  • 1. A Single Dose Respiratory Recombinant Adenovirus-Based Vaccine Provides Long-Term Protection for Non-Human Primates from Lethal Ebola Infection.
    Choi JH; Jonsson-Schmunk K; Qiu X; Shedlock DJ; Strong J; Xu JX; Michie KL; Audet J; Fernando L; Myers MJ; Weiner D; Bajrovic I; Tran LQ; Wong G; Bello A; Kobinger GP; Schafer SC; Croyle MA
    Mol Pharm; 2015 Aug; 12(8):2712-31. PubMed ID: 25363619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bolstering Components of the Immune Response Compromised by Prior Exposure to Adenovirus: Guided Formulation Development for a Nasal Ebola Vaccine.
    Choi JH; Schafer SC; Freiberg AN; Croyle MA
    Mol Pharm; 2015 Aug; 12(8):2697-711. PubMed ID: 25549696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal immunization with an adenovirus vaccine protects guinea pigs from Ebola virus transmission by infected animals.
    Wong G; Richardson JS; Cutts T; Qiu X; Kobinger GP
    Antiviral Res; 2015 Apr; 116():17-9. PubMed ID: 25596432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates.
    Richardson JS; Pillet S; Bello AJ; Kobinger GP
    J Virol; 2013 Apr; 87(7):3668-77. PubMed ID: 23302894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine.
    Richardson JS; Yao MK; Tran KN; Croyle MA; Strong JE; Feldmann H; Kobinger GP
    PLoS One; 2009; 4(4):e5308. PubMed ID: 19390586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of systemic or mucosal immunity to adenovirus on Ad-based Ebola virus vaccine efficacy in guinea pigs.
    Richardson JS; Abou MC; Tran KN; Kumar A; Sahai BM; Kobinger GP
    J Infect Dis; 2011 Nov; 204 Suppl 3():S1032-42. PubMed ID: 21987739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial.
    Li JX; Hou LH; Meng FY; Wu SP; Hu YM; Liang Q; Chu K; Zhang Z; Xu JJ; Tang R; Wang WJ; Liu P; Hu JL; Luo L; Jiang R; Zhu FC; Chen W
    Lancet Glob Health; 2017 Mar; 5(3):e324-e334. PubMed ID: 28017642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs.
    Choi JH; Schafer SC; Zhang L; Kobinger GP; Juelich T; Freiberg AN; Croyle MA
    Mol Pharm; 2012 Jan; 9(1):156-67. PubMed ID: 22149096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
    Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY
    J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice.
    Bengtsson KL; Song H; Stertman L; Liu Y; Flyer DC; Massare MJ; Xu RH; Zhou B; Lu H; Kwilas SA; Hahn TJ; Kpamegan E; Hooper J; Carrion R; Glenn G; Smith G
    Vaccine; 2016 Apr; 34(16):1927-35. PubMed ID: 26921779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques.
    Singh K; Marasini B; Chen X; Ding L; Wang JJ; Xiao P; Villinger F; Spearman P
    J Virol; 2020 Apr; 94(9):. PubMed ID: 32075939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ebola-GP DNA Prime rAd5-GP Boost: Influence of Prime Frequency and Prime/Boost Time Interval on the Immune Response in Non-human Primates.
    Marcus H; Thompson E; Zhou Y; Bailey M; Donaldson MM; Stanley DA; Asiedu C; Foulds KE; Roederer M; Moliva JI; Sullivan NJ
    Front Immunol; 2021; 12():627688. PubMed ID: 33790899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of Immune Responses Induced by Ebola Virus Glycoprotein (GP) and Truncated GP Isoform DNA Vaccines and Protection Against Lethal Ebola Virus Challenge in Mice.
    Li W; Ye L; Carrion R; Mohan GS; Nunneley J; Staples H; Ticer A; Patterson JL; Compans RW; Yang C
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S398-403. PubMed ID: 25877553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.
    Konduru K; Shurtleff AC; Bradfute SB; Nakamura S; Bavari S; Kaplan G
    PLoS One; 2016; 11(9):e0162446. PubMed ID: 27622456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates.
    Marzi A; Engelmann F; Feldmann F; Haberthur K; Shupert WL; Brining D; Scott DP; Geisbert TW; Kawaoka Y; Katze MG; Feldmann H; Messaoudi I
    Proc Natl Acad Sci U S A; 2013 Jan; 110(5):1893-8. PubMed ID: 23319647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge.
    Bukreyev A; Yang L; Zaki SR; Shieh WJ; Rollin PE; Murphy BR; Collins PL; Sanchez A
    J Virol; 2006 Mar; 80(5):2267-79. PubMed ID: 16474134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses.
    Meyer M; Garron T; Lubaki NM; Mire CE; Fenton KA; Klages C; Olinger GG; Geisbert TW; Collins PL; Bukreyev A
    J Clin Invest; 2015 Aug; 125(8):3241-55. PubMed ID: 26168222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs.
    Sullivan NJ; Geisbert TW; Geisbert JB; Shedlock DJ; Xu L; Lamoreaux L; Custers JH; Popernack PM; Yang ZY; Pau MG; Roederer M; Koup RA; Goudsmit J; Jahrling PB; Nabel GJ
    PLoS Med; 2006 Jun; 3(6):e177. PubMed ID: 16683867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.
    Mire CE; Matassov D; Geisbert JB; Latham TE; Agans KN; Xu R; Ota-Setlik A; Egan MA; Fenton KA; Clarke DK; Eldridge JH; Geisbert TW
    Nature; 2015 Apr; 520(7549):688-691. PubMed ID: 25853476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector.
    Pratt WD; Wang D; Nichols DK; Luo M; Woraratanadharm J; Dye JM; Holman DH; Dong JY
    Clin Vaccine Immunol; 2010 Apr; 17(4):572-81. PubMed ID: 20181765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.